<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133679</url>
  </required_header>
  <id_info>
    <org_study_id>K23HL079922-01</org_study_id>
    <nct_id>NCT00133679</nct_id>
  </id_info>
  <brief_title>Chronic Sildenafil for Severe Diaphragmatic Hernia</brief_title>
  <official_title>Chronic Sildenafil for Severe Diaphragmatic Hernia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if sildenafil is effective in the treatment of infants&#xD;
      with severe congenital diaphragmatic hernia (determined by the presence of prolonged&#xD;
      pulmonary hypertension or prolonged oxygen supplementation on mechanical ventilation), as&#xD;
      measured by the estimated pulmonary artery systolic pressure following treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital diaphragmatic hernia (CDH) is a condition characterized by pulmonary parenchymal&#xD;
      and vascular hypoplasia. Severe CDH carries a high rate of mortality, and significant&#xD;
      morbidity among survivors. This proposal is a randomized, blinded, placebo-controlled study&#xD;
      designed to evaluate the efficacy and potential mechanisms of activity of sildenafil, a&#xD;
      phosphodiesterase-5 inhibitor, for treatment of severe CDH. Infants who meet criteria at â‰¥10d&#xD;
      of age predicting a poor outcome [death or chronic lung disease (CLD) severe enough to&#xD;
      require hospital discharge on supplemental oxygen (O2)] will be eligible for the study.&#xD;
      Infants whose parents consent for the study will undergo an initial echocardiogram to assess&#xD;
      the degree of pulmonary hypertension. They will then begin either sildenafil or placebo&#xD;
      therapy for a 45d course. A final echocardiogram will be performed after the experimental&#xD;
      drug course is completed. The pulmonary arterial systolic pressure estimate during hyperoxic&#xD;
      conditions will be compared between the sildenafil and placebo groups. Infants from either&#xD;
      group who have severely elevated pulmonary arterial pressure (despite supplemental O2) will&#xD;
      be considered for open-label sildenafil, which will continue after hospital discharge,&#xD;
      depending on the results of a cardiac catheterization performed for clinical care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with&#xD;
    possibility of placebo beyond 6 weeks of age on study protocol&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Systolic Pulmonary Arterial Pressure at Final Echocardiogram</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Levels of Vasoactive Substances at the Time of Final Echocardiogram</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects of Sildenafil Therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic Growth at 1 and 2 Years of Age</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Outcome at 1 and 2 Years of Age</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Status at 1 and 2 Years of Age</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hernia, Diaphragmatic</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Hypoplasia, Pulmonary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil x 45 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 45 d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Viagra, Revatio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo suspension (equal volume to experimental drug) x 45 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Congenital diaphragmatic hernia&#xD;
&#xD;
          -  10-42 days (d) of age&#xD;
&#xD;
          -  Significant illness severity as demonstrated by:&#xD;
&#xD;
          -  Receiving assisted ventilation and&#xD;
&#xD;
               -  FiO2 &gt;= 0.40 at 10-14d of age, or&#xD;
&#xD;
               -  FiO2 &gt;= 0.40 for &gt;=48hours at 15-27d of age, or&#xD;
&#xD;
               -  FiO2 &gt;= 0.35 at 28-42d of age&#xD;
&#xD;
          -  Or, need for extracorporeal support at &gt;=10d of age&#xD;
&#xD;
          -  Or, estimated pulmonary arterial or right ventricular systolic pressure of &gt;= 2/3&#xD;
             systemic pressure at 14-42d of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Structural congenital heart disease (other than patent ductus arteriosus or patent&#xD;
             foramen ovale/atrial septal defect [ASD] or non-hemodynamically significant&#xD;
             ventricular septal defect [VSD])&#xD;
&#xD;
          -  Sildenafil contraindicated (until condition resolves):&#xD;
&#xD;
               -  Unable to absorb oral medication, or&#xD;
&#xD;
               -  Unstable systemic blood pressure, or&#xD;
&#xD;
               -  Receiving a drug that may interfere with sildenafil metabolism, or&#xD;
&#xD;
               -  Renal insufficiency&#xD;
&#xD;
               -  Hepatic insufficiency Previous use of sildenafil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta L Keller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <results_first_submitted>December 7, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2021</results_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lung disease</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>cyclic guanosine monophosphate</keyword>
  <keyword>phosphodiesterase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hernias, Diaphragmatic, Congenital</mesh_term>
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Diaphragmatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil</title>
          <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil</title>
          <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Systolic Pulmonary Arterial Pressure at Final Echocardiogram</title>
        <time_frame>7 weeks</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Systolic Pulmonary Arterial Pressure at Final Echocardiogram</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Levels of Vasoactive Substances at the Time of Final Echocardiogram</title>
        <time_frame>7 weeks</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Levels of Vasoactive Substances at the Time of Final Echocardiogram</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects of Sildenafil Therapy</title>
        <time_frame>2 years</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects of Sildenafil Therapy</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Somatic Growth at 1 and 2 Years of Age</title>
        <time_frame>2 years</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Somatic Growth at 1 and 2 Years of Age</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental Outcome at 1 and 2 Years of Age</title>
        <time_frame>2 years</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Neurodevelopmental Outcome at 1 and 2 Years of Age</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Status at 1 and 2 Years of Age</title>
        <time_frame>2 years</time_frame>
        <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Status at 1 and 2 Years of Age</title>
          <population>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</time_frame>
      <desc>Study was terminated. All efforts to locate the data have been exhausted and data has been lost and/or destroyed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil</title>
          <description>Sildenafil x 45 days&#xD;
sildenafil: Sildenafil 0.5 mg/kg every 6 hours orally x 45 d</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo x 45 d&#xD;
Placebo: Placebo suspension (equal volume to experimental drug) x 45 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roberta Keller, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-1888</phone>
      <email>roberta.keller@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

